MO40-4 DCF Regimen Might Be Useful As Neo-Adjuvant Chemotherapy for Esophageal Cancer from Our Institutional Experience
ANNALS OF ONCOLOGY(2023)
摘要
In January 2022, at the ASCO GI meeting, the results of the JCOG1109 trial were announced, making three courses of DCF (DOC+CDDP+5-FU) therapy the new standard neo-adjuvant chemotherapy regimen for stage II/III esophageal cancer. We experienced a case of esophageal cancer that received curative resection and DCF therapy after failure of CF. Given this successful outcome, we have aggressively performed DCF therapy since November 2014. In the early stage, we perform two courses of DCF at four-week intervals.
更多查看译文
关键词
Neoadjuvant Chemotherapy,Neoadjuvant Therapy,Adjuvant Therapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn